Steven Clausnitzer

So how does it help me, actually, in the future?

So I mentioned briefly there's over 500 clinical trials using these cells.

These trials are not for some fringe diseases.

We're talking about cardiovascular disease, stroke, Alzheimer's.

And some of these are in phase three.

Cardiovascular disease and stroke are in phase three.

That's the number one and the number three killer of our species, respectively.

So what they're finding is you can, for example,

At Johns Hopkins, they took these bone marrow-derived mesenchymal stem cells, the same ones we store for you, and they grew them and introduced them into the damaged area of a person's heart after they had a heart attack.

And they were able to grow healthy tissue, replace damaged, scarred tissue with healthy tissue.

But here, check it out.

Here's what sucks.

There's a number of people that wanted to participate in that trial but couldn't because when they isolated their cells and they looked at them, there weren't enough of them there.

And the ones that were there wouldn't grow because that 80-year-old man was too old.

Had he stored his 28-year-old stem cells, that's not a problem.

So part of what we're doing here, Nathan, is very pragmatic, very practical.

You'll have the best possible treatments in the future using these cells.

Now, the moonshot and what we're most excited about and, frankly, why we started the company is because what we want to do, and we're already doing it in animals at Forever Labs, we're taking cells from young mice and we're putting them in genetically matched older mice because I should really start at the beginning here.

We started the company because I was on the phone

And you'll find this a year, by the way, this is two years ago.